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Adrenal suppression secondary to prolonged inhaled corticosteroid use is usually limited to biochemical abnormalities, with no
obvious clinical eﬀects. Acute adrenal crisis is much rarer event but has been reported with increasing frequency. We report a case
of a 7-year-old asthmatic child who presented with an acute history of lethargy after a respiratory infection. He was maintained
on 220µg/day of ﬂuticasone propionate for several years. Initial evaluation revealed severe adrenal suppression, with undetectable
cortisol levels and minimal response after stimulation with ACTH. After ﬂuticasone was discontinued, a gradual recovery of the
adrenal axis was seen. This case shows that acute adrenal crisis may be a consequence even at the usual prescribed doses, stressing
the importance of using the lowest dose of inhaled steroids needed to control symptoms and having an increased awareness of this
complication.
1.Introduction
Inhaled corticosteroids (ICSs) are a cornerstone for the
treatmentofasthma,proventobeveryeﬀectiveinitsdecades
of use. They prevent asthma exacerbations, maximize lung
function, and are the only treatment for chronic asthma
shown to reduce asthma-related deaths [1]. Inhaled steroids
include beclomethasone, budesonide, ﬂuticasone dipropi-
onate, mometasone furoate, and triamcinolone acetate.
While all inhaled steroids work by binding to a common
glucocorticoid receptor, the potency of each medication dif-
fers, as well as the side eﬀect proﬁle. Fluticasone propionate
has been in use since the 1990s and is more potent than its
predecessors. It has equivalent eﬃcacy when given at half the
daily dose of the older medications, beclomethasone dipro-
prionate and budesonide [2]. Its favorable pharmacologic
properties include a higher aﬃnity for glucocorticosteroid
receptors, higher lipophilicity, and greater lung deposition.
Side eﬀects were thought to be lower due to less oral
systemic absorption due to an almost complete ﬁrst pass
hepatic clearance (almost 99%) of the swallowed part of the
medication (at least 70% of emitted dose) [3, 4]. At the
recommended daily dose in children of 100–200µg, there
is a good safety proﬁle, with limited eﬀects on the adrenal
function or growth. However, such side eﬀects are seen
starting at a dose of 400µg/day, particularly when given for
a prolonged period [5]. When adrenal suppression is seen
in patients, it is usually limited to laboratory abnormalities.
Acute adrenal insuﬃciency is less common but has been
reported with increasing frequency over the past decade,
especially as ﬂuticasone use has become widespread [4]. We
report a case of a 7-year-old asthmatic child who presented
with adrenal crisis while on a dose of 220µg/day of ﬂuticas-
one proprionate, lower than the usual suppressive dose.
2.Case
A 7-year-old asthmatic child presented to the emergency
department with a 1 day history of fever, cough, vomiting,
andlethargy.Hehadbeenmaintainedoninhaledﬂuticasone,
220µg/day (110ugBID) for the past four years. He had
brieﬂy used a 440µg/day dose for a few months two years
prior. He has no oral prednisone use for the past year.
Signiﬁcant in the past medical history is an episode of acute
gastroenteritis 10 months prior, which led to hypovolemic2 International Journal of Pediatric Endocrinology
shock, accompanied by hypoglycemia and altered mental
status. He was admitted to the PICU and required ﬂuid
resuscitation and vasopressors. He recovered completely
from this. No adrenal work-up was done at that time. In
the present ED visit, initial vital signs showed a BP 108/60,
HR128/min, RR 24/min, temperature 101.2F. He appeared
lethargic and acutely ill. The rest of the physical exam was
unremarkable. Initial lab work revealed normal electrolytes
and liver function, with a normal glucose of 116mg/dl
( 6 . 4m m o l / L ) .H eh a dan o r m a lW B C ,b u tw i t hg r a n u l o c y t e
predominance. Cortisol at that time was <8.28nmol/L
(normal afternoon cortisol 63.48–328.44nmol/L). He was
given intravenous normal saline and IV hydrocortisone,
which provided immediate improvement. Consultation with
a pediatric endocrinologist was made, who noted that he
had a mildly Cushingoid appearance. There was no skin
hyperpigmentation. A review of the growth chart showed
a decline of his height from the 60% to the 13% on the
preceding year while his weight increased 55% from 65%.
A 250µg ACTH stimulation test was done, where a basal
cortisol of 19.32nmol/L only increased to 35.88nmol/L in
60mins. Because of the history of receiving inhaled steroids,
secondary adrenal suppression was suspected. Prolonged
stimulation test was performed (8-hour ACTH infusion for
3 days), with cortisol level peaking to 361.56nmol/L on
day 3. This showed an ability of the adrenals to respond,
making secondary adrenal suppression more likely. The
ACTH level drawn in the ED came back at this time and
was elevated at 89.98pmol/L (normal 1.3–10.56pmol/L).
Adrenal antibodies were negative. With the guidance of a
pulmonologist, the child was completely weaned oﬀ inhaled
steroids and switched to oral Singulair (Montelukast). The
child recovered quickly with no complications. The family
was taught to do stress dosing with hydrocortisone in case
of illness. On outpatient followup a month after steroid
discontinuation, he remained well. Electrolytes remained
normal, morning (AM) cortisol was 110.4nmol/L (normal
171.12–535.4nmol/L), and ACTH level was 22.6pmol/L
(see Table 1). Two months oﬀ steroids, AM cortisol was
187.68nmol/L and ACTH level was 22.2pmol/L. 9 months
oﬀ steroids, his AM cortisol was 292.56nmol/L and ACTH
was 14.74pmol/L. 16 months after, a low-dose (1µg) ACTH
stimulation test showed a peak cortisol of 477.48nmol/L.
Throughout this period, the child needed stress dosing once
for a viral illness from which he recovered immediately.
His asthma has remained well controlled on his current
regimen. He had catch-up growth, with height now at
the 35th percentile, and his Cushingoid appearance has
resolved.
3. Discussion
Secondaryadrenalsuppressionisawell-knowncomplication
of long-term administration of high doses of steroids, with
diﬀerent propensities depending on the route of admin-
istration. Excess steroids result in negative feedback on
the hypothalamic-pituitary-adrenal axis, rendering the body
incapable of mounting a stress response in times of increased
need. Symptoms of adrenal insuﬃciency may be nonspeciﬁc
likefatigue,anorexia,vomiting,andabdominalpainbutmay
also lead to a life-threatening adrenal crisis accompanied
by shock [5, 6]. Inhaled corticosteroids (ICSs) have been
widely used since its introduction, not only because of its
eﬃcacy, but also because it is thought to have decreased
toxicityfromthelowersystemicabsorptioncomparedtooral
steroids. However, toxicity is commonly seen especially with
prolonged use of high doses.
Multiple studies have attempted to estimate the propen-
sity of inhaled corticosteroids (ICSs) to cause adrenal
suppression. In a systematic review of literature from 1973
to 2005, 22 studies were analyzed to evaluate hypothalamic-
pituitary-adrenal axis suppression from inhaled steroids,
as determined by gold standard tests like metyrapone or
insulin tolerance tests. The best data was a cohort study
published in 1982 by Vaz et al. showing that there was
a 100% absolute risk of adrenal suppression in asthmatic
children treated with beclomethasone metered dose inhaler
at a dose of 250–600µg/m2/day for 6–42 months. Studies
suggest that this may be similar with other ICSs [7, 8]. A
meta-analysis examined dose-related response and adrenal
suppression of inhaled ﬂuticasone, assessing double blinded
randomizedcontrolledtrialsfrom1980to2002andincluded
seven studies of 1733 children. Based on a dose response
curve,ﬂuticasone’seﬃcacyseemstoplateaubetween100and
200µg. A dose of 400µg was shown to give additional beneﬁt
particularly for severe asthmatics, but adrenal suppression
also was seen at this dose [9]. In a study of 220 children
on high dose (>500µg/day) inhaled ﬂuticasone, a low-dose
ACTH test showed that 45% of the children had ﬂat or
impaired response (peak cortisol <500nmol/L) [10]. While
biochemical adrenal suppression is well described, acute
a d r e n a lc r i s i si sl e s sc o m m o n ,a n dt h ea c t u a lp r e v a l e n c e
is not known. In a review of inhaled corticosteroid use
in 1994, Russell wrote that there was no ﬁrm evidence of
a d r e n a lc r i s i s[ 11]. Until 1999, there were only 2 cases of
adrenal crises reported in its 30 years of use. Since then,
there have been an increasing number of reports of adrenal
crisis, including case reports, case series, and a survey [12].
In the survey done in UK, 33 patients (28 children, 5 adults)
were identiﬁed to have adrenal crisis. 23 of the children
presented with hypoglycemia, accompanied with decreased
level of consciousness, seizures, or death in 1. All identiﬁed
patients were treated with 500–2000µg/day ICS, with 94%
receiving ﬂuticasone. The majority (76%) of the patients
were treated for at least a year. Fluticasone accounted for
the smallest percentage of prescriptions for ICS in that
area, making the authors conclude that ﬂuticasone had a
higher propensity for adrenal suppression [4]. A possible
explanation for this is ﬂuticasone’s high lipophilicity. While
the high hepatic clearance of ﬂuticasone oﬀe r sl e s ss y s t e m i c
absorption, absorption via the lungs into the bloodstream
remains an important source of systemic ICS, as this escapes
ﬁrst pass metabolism. Fluticasone is 200–300 times more
lipophilic than budesonide and beclomethasone and results
in a greater volume of distribution. This causes higher
binding in peripheral tissues, longer elimination half-life,
and more accumulation [4].International Journal of Pediatric Endocrinology 3
Table 1: Patient’s laboratory results showing initial adrenal suppression and subsequent recovery after steroid discontinuation.
Cortisol (nmol/L) ACTH (pmol/L)
Patient values Normal range Patient values Normal range
(a) On inhaled steroids
Initial <8.3 63.5–328.4 (PM) 409 1.3–10.56
250µgA C T Ht e s t ,
Baseline
19.3
250µgA C T Ht e s t ,
Stimulated
35.9 >500
3 day ACTH-peak 361.6 >500
(b) After steroid discontinuation
1m o n t h 110.4 171.1–535.4 (AM) 22.6 1.3–10.56
2m o n t h s 187.68 171.1–535.4 22.2
9m o n t h s 292.56 171.1–535.4 14.7
16 months
(1µg ACTH test, peak)
477.48 >500 7.04
Aside from diﬀerences between the inhaled steroids,
interindividual variations may also account for diﬀerences
in glucocorticoid sensitivity. This may be due to diﬀerences
in cortisol metabolism, as well as genetic variations in
the glucocorticoid receptor (GR). Steroids act primarily
through a target cytoplasmic GR, which is part of a more
complicated GR complex with various components. Due
to the complexity of this complex, there has been so far
limited pharmacogenetic information useful in the clinical
setting. There have been mutations identiﬁed with NR3C1,
which is the gene encoding for the GR, mostly associated
with glucocorticoid resistance [13]. Variations in codon
363 of the glucocorticoid receptor (N363S) have been
associated with an increased sensitivity to glucocorticoids
in vivo [14]. Drug-drug interactions also may account
for increased toxicity from inhaled steroids. Fluticasone as
well as budesonide is metabolized mainly by CYP3A4, and
drugs that inhibit this enzyme increase the bioavailability
of the inhaled steroids, just as in steroids taken orally
and parenterally. This subsequently increases the risk for
systemic adverse reactions. This is well demonstrated in a
case series of 46 patients on inhaled steroids who developed
adrenal insuﬃciency. Fifteen of the cases were possibly
due to a drug interaction with known cytochrome p450
inhibitors, including itraconazole, ritonavir, verapamil, and
diltiazem [15]. Other known inhibitors include etomidate,
diltiazem, and grapefruit juice. Drugs that activate cortisol
metabolism may also cause adrenal insuﬃciency in patients
with limited adrenal reserves, or those on replacement glu-
cocorticoidtreatment.Thisincludesphenytoin,barbiturates,
and rifampin [5]. The child in our case report had no history
of use of any of the aforementioned medications.
There are several etiologies which must be considered
for a childhood onset adrenal disease. Hereditary disorders
include autoimmune adrenal disease, which may be part
of autoimmune polyglandular syndrome. In the Western
hemisphere, this autoimmune disease is responsible for
up to 80% of cases of primary adrenal failure [16]. Our
patient had negative antiadrenal antibodies on screening.
Adrenomyeloneuropathy is a milder form of the x-linked
recessive disorder adrenoleukodystrophy, both occurring at
frequency of 1 in 20,000 males, and may account for up
to 10% of all cases of adrenal failure. Both present with
adrenal insuﬃciency as well as spasticity and weakness.
Adrenomyeloneuropathy has a later onset at adolescence
and adulthood and has a slower and milder course. A
vital consideration is that adrenal insuﬃciency may be the
only presenting symptom in this condition. The defect is
in the beta-oxidation of fatty acids in the peroxisomes,
and diagnosis is shown by elevated serum very-long-
chain fatty acids (VLCFA) [16]. Other etiologies include
late onset congenital adrenal hyperplasia (such as from
21-hydroxylase deﬁciency), congenital adrenal hypoplasia,
inﬁltrative adrenal disease (tuberculosis, HIV, and fungal
infection), and adrenal hemorrhage. With the absence of
other associated clinical signs and symptoms, and adrenal
recovery after steroid weaning in this patient, a complete
work-up for these other etiologies was not pursued.
The child’s initial blood tests of low cortisol and high
ACTH levels, as well as the poor response to the standard
ACTH stimulation test, can be suggestive of primary adrenal
disease. However, the child did not have any signs of
aldosterone deﬁciency (he had normal electrolytes) and no
clinical signs of skin hyperpigmentation and salt craving
which usually accompany a primary adrenal problem. There
remained a strong suspicion of secondary adrenal suppres-
sion from his clinical history, so a prolonged ACTH test
was then done. In most cases, this test is rarely necessary as
clinicalhistory, physicalexam,andsingle-dose ACTH testing
may provide the diagnosis. However, for certain patients like
ourswherethediagnosismaynotbeasclearcut,thiscanhelp
further diﬀerentiate primary from secondary/tertiary cause
of adrenal insuﬃciency. 250µgo fA C T Hw a sgi v e nf o r3d a y s
via an 8-hour infusion, with multiple cortisol levels drawn
at diﬀerent time points [5, 17]. Elevation of plasma cortisol
level in the child at the last day of the infusion conﬁrmed the
secretory capacity of the adrenals. The gradual recovery of
the adrenal axis after steroid weaning further strengthened4 International Journal of Pediatric Endocrinology
the diagnosis of secondary adrenal suppression. The initial
blood tests with an elevated ACTH level can be explained by
the quicker recovery of the hypothalamic-pituitary axis from
secondary suppression as compared to the adrenal gland.
This case provides further evidence that potentially
life-threatening adrenal crisis may occur from prolonged
inhaled corticosteroid use. Package insert for ﬂuticasone
(in particular Flovent) recommends 88µg BID for children
less than 12years old, but many physicians use it at higher
doses particularly in severe asthma. While most cases of
adrenal crisis are seen with >400µg/day, this child was
maintained on 220µg/day for the past year, stressing the
role of individual patient sensitivity to steroids. The child’s
history is signiﬁcant for hypovolemic shock following an
acute gastroenteritis, which in hindsight was likely to be an
episode of adrenal crisis. Unfortunately, suspicion of adrenal
insuﬃciency arose only on the more recent ED visit. This
emphasizes the importance for physicians to be aware of
this complication, especially as this is a very commonly
prescribed medication. It is therefore vital to periodically
reassess a child’s asthma status, with the aim of tapering
to the lowest eﬀective dose and subsequently minimizing
systemic side eﬀects. For evaluation of at-risk patients, the
low-dose (0.5–1µg) ACTH stimulation test is thought to be
moresensitivefordiagnosingsecondaryadrenalsuppression,
astheusual250µgdoseissupraphysiologicandmightleadto
false negative results. However, some studies do not support
the superiority of one test over the other, particularly as both
may lead to false negative results [15].
4. Conclusion
Inhaled steroids are indispensible in the treatment of chronic
asthma, but their prolonged use at doses higher than
recommended increases the risk of adrenal suppression. This
case shows that life-threatening adrenal crisis may be a
consequence even at the usual prescribed doses, stressing
the importance of using the lowest dose of inhaled steroids
needed to control symptoms and being vigilant of side
eﬀects.
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